Note 5 - License Agreements (Details)	1 Months Ended	3 Months Ended	9 Months Ended			39 Months Ended					9 Months Ended	1 Months Ended					9 Months Ended		39 Months Ended				1 Months Ended							1 Months Ended	9 Months Ended		1 Months Ended		0 Months Ended							9 Months Ended
	Mar. 31, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($)		Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($)		Apr. 30, 2013 USD ($)	Dec. 31, 2012 USD ($)		Sep. 30, 2013 Achievement of Milestoe Marks [Member] iCo [Member] USD ($)	Mar. 31, 2012 Annual Installments [Member] MabLife [Member] Exclusive License Rights [Member] USD ($)	Apr. 30, 2012 Execution of Agreement [Member] MabLife [Member] USD ($)	Jun. 30, 2011 Ordinary Shares [Member] iCo [Member] USD ($)	Jun. 30, 2011 iCo [Member] Cash Payment [Member] USD ($)	Jun. 30, 2011 iCo [Member] Exclusive License Rights [Member] USD ($)	Sep. 30, 2013 iCo [Member] USD ($)	Sep. 30, 2012 iCo [Member] USD ($)	Sep. 30, 2013 iCo [Member] USD ($)	Dec. 31, 2012 iCo [Member] USD ($)	Jun. 30, 2011 iCo [Member] USD ($)	Sep. 30, 2013 iCo [Member] From inception [Member]	Apr. 30, 2011 Yissum [Member] License Maintenance Fee [Member] USD ($)	Apr. 30, 2011 Yissum [Member] Max Amount of Maintenance Fee Year One - Year Six [Member] USD ($)	Apr. 30, 2011 Yissum [Member] Research Fee [Member] USD ($)	Apr. 30, 2011 Yissum [Member] Research Fees year 2-6 [Member] USD ($)	Apr. 30, 2011 Yissum [Member] Aggregate Research Fees, Maximum [Member] USD ($)	Apr. 30, 2011 Yissum [Member] USD ($)	Apr. 30, 2013 MabLife [Member] Present Value [Member] USD ($)	Mar. 31, 2012 MabLife [Member] USD ($)	Sep. 30, 2013 MabLife [Member] USD ($)	Apr. 30, 2013 MabLife [Member] USD ($)	Mar. 31, 2011 Kadouche [Member] Cash Payment [Member] USD ($)	Mar. 31, 2011 Kadouche [Member] Exclusive License Rights [Member] USD ($)	May 02, 2012 Lonza [Member] Annual Payments - License Cost [Member] USD ($)	May 02, 2012 Lonza [Member] Annual Payments - License Cost [Member] EUR (€)	May 02, 2012 Lonza [Member] Annual Payments, Sublicense [Member] USD ($)	May 02, 2012 Lonza [Member] Annual Payments, Sublicense [Member] EUR (€)	May 02, 2012 Lonza [Member] Cell Line Payments [Member] USD ($)	May 02, 2012 Lonza [Member] Cell Line Payments [Member] EUR (€)	May 02, 2012 Lonza [Member]	Sep. 30, 2013 Shire BioChem (Member) USD ($)
Note 5 - License Agreements (Details) [Line Items]
License Costs												$ 600,000	$ 60,000		$ 500,000	$ 1,700,000							$ 30,000	$ 100,000	$ 400,000	$ 400,000	$ 1,800,000						$ 20,298	$ 700,000	$ 113,873	€ 75,000	$ 500,000	€ 300,000	$ 3,045	€ 2,000
Stock Issued During Period, Shares, Other (in Shares)	800,000													600,000														800,000
Stock Issued During Period, Value, Other	700,000													1,000,000														700,000
Shares Issued, Price Per Share (in Dollars per share)														$ 1.72														$ 0.87
Class of Warrant or Right, Issued																					200,000
Convertible Debt, Fair Value Disclosures (in Dollars)																					200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)																					0.95
Percent of Company's Issued and Outstanding Share Capital																					6.14%
Dilution Rate																					2.50%
Pre-Money Valuation Minimum																					30,000,000
Derivative Liability																	0		0	600,000	800,000
(in Dollars)		26,000	74,000		51,000	58,000											74,242	24,864	58,388
Common Stock, Shares Authorized (in Shares)			225,000,000			225,000,000			225,000,000								350,013	44,233	350,013			458,621
Milestone Payments																	32,000,000											8,600,000
Royalty Rate, Milestone Payments																	8.50%
Licenses Revenue											100,000,000
Royalty Rate, Percent of Net Sales																												4.50%		0.60%											1.00%
Percent of Sub-License Consideration																												18.00%
Fair Value of Annual License Costs																														400,000
Interest Rate on License Costs																														12.00%
Interest Expense, Other					23,278																										32,990
Operating Leases, Future Minimum Payments Due		100,000			100,000																											80,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months																																100,000
Operating Leases, Future Minimum Payments, Due in Two Years																																120,000
Operating Leases, Future Minimum Payments, Due in Three Years								120,000
Operating Leases, Future Minimum Payments, Due in Four Years								120,000
Operating Lease, Present Value of Future Payments																													400,000
Notes Payable, Current																															140,660
Notes Payable, Noncurrent			376,000	[1]		376,000	[1]		376,000	[1]																					235,116
Royalty Rate Net Selling Price Of The Product																																					2.00%	2.00%			1.50%
Effect on Future Cash Flows, Amount																																										$ 26,000,000

[1] In March 2012, the Company acquired from MabLife, through an assignment agreement, all rights, titles and interests in and to the patent rights, technology and deliverables related to the anti-Ferritin mAb, AMB8LK, including its nucleotide and protein sequences, its ability to recognize human acid and basic ferritins, or a part of its ability to recognize human acid and basic ferritins. The consideration is as follows: (i) $600,000 payable in six annual installments (one of such installments being an upfront payment made upon execution of the agreement) with a fair value of $435,775 and an interest rate of 12%; and (ii) royalties of 0.6% of net sales of any product containing AMB8LK or the manufacture, use, sale, offering or importation of which would infringe on the patent rights with respect to AMB8LK. Immune is required to assign the foregoing rights back to MabLife if Immune fails to make any of the required payments, is declared insolvent or bankrupt or terminates the agreement. $60,000 was paid to MabLife upon execution of agreement in April 2012 and $32,990 and $23,278 of interest was expensed during the nine months ended September 30, 2013 and 2012, respectively. Future payments are due annually in the following amounts: $80,000 in April, 2013, the payment due date for which has been extended to December 31, 2013, $100,000 in April 2014, and $120,000 on each of the following three anniversaries from April 2015 through April 2017. The present value of future payments is $375,775; $140,660 of which was determined to be short term and $235,116 of which was determined to be long term and has been recorded as notes payable on the balance sheet.